Dr. Kaufman Discusses Durable Responses to Avelumab in Merkel Cell Carcinoma
Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.
Suggested videos

Dr. Monk on the Utility of Bevacizumab for Cervical Cancer
Targeted Onc · 1:47

Dr. Howard Kaufman on Merkel cell carcinoma
Vital Options International · 4:12

Treatment Approach for Nondriver Lung Adenocarcinoma
Targeted Onc · 7:12

Durable responses to avelumab in patients with Merkel cell carcinoma
ecancer · 2:18

The Future of Cancer Research: Insights From Dr Ferris
Targeted Onc · 4:40

Dr. Lebbe Discusses Efficacy of Avelumab in Merkel Cell Carcinoma
OncLive · 1:38

Adopting PACIFIC Data Into Practice
Targeted Onc · 6:23

Dr. Kudchadkar on the FDA Approval of Avelumab in Merkel Cell Carcinoma
OncLive · 0:35

Tailoring Therapy for Patients With DLBCL
Targeted Onc · 2:01

Using Immuno-oncology Agents in Merkel Cell Carcinoma
Cancer Therapy Advisor · 2:11

Current Standard of Care for Frontline CLL
Targeted Onc · 1:58

Avelumab in combinations for lung cancer and update from ALEX study
ecancer · 7:11